Non-Alcoholic Steato Hepatitis (NASH) Outlook 2016

Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025! 

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year. 

View complete report @ http://www.reportsweb.com/rising-stars-outlook-2016-new-emergence-of-potential-tx-and-dx-options-could-transform-the-current-landscape-for-liver-diseases-nash . 

Request a sample @ http://www.reportsweb.com/inquiry&RW0001173053/sample . 

Few points from ToC:

4. Genfit SA (GNFT)
- GNFT offers Remarkable NASH Treatment Package: Robust Drug + Non-Invasive Biomarker Test

- KEY MILESTONES (GNFT)
- Figure 1 Genfit SA GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
- Figure 2 Genfit SA GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
- Table 1 Genfit SA COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Table 1 Genfit SA – Continued COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 3 Genfit SA ELAFIBRANOR: PPAR REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH
- CLINICAL DEVELOPMENT

-Figure 4 Genfit SA ELAFIBRANOR: PHASE III TRIAL DESIGN
- Figure 5A Genfit SA GOLDEN-505: IMPROVEMENT IN CARDIO-METABOLIC AND GLYCEMIC PARAMETERS
- Figure 6 Genfit SA EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
- Figure 7 Genfit SA EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
- Figure 8 Genfit SA EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS 
- Figure 8 Genfit SA – Continued EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS  

Order a copy of this complete report @ http://www.reportsweb.com/buy&RW0001173053/buy/2000 .